UPDATE: UBS Starts Moderna (MRNA) at Neutral

January 21, 2022 5:53 AM EST
Get Alerts MRNA Hot Sheet
Price: $142.26 +4.40%

Rating Summary:
    8 Buy, 12 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 16 | Down: 16 | New: 10
Trade Now! 
Join SI Premium – FREE
(Updated - January 21, 2022 5:53 AM EST)

UBS analyst Eliana Merle initiates coverage on Moderna (NASDAQ: MRNA) with a Neutral rating and a price target of $221.00.

The analyst comments "We took a detailed look at MRNA’s pipeline beyond COVID-19 and we see mRNA as a disruptive force in the $35B+ global annual vaccine market (beyond COVID-19). We think MRNA's platform has significant applications beyond COVID-19, but that current levels reflect this potential based on the science to date. In the near-term, we think COVID-19 remains the key focus and a source of near-term volatility for shares. We see some potential further headwinds for shares amidst the uncertainty as COVID-19 transitions from a pandemic to endemic disease. Long-term, we think the success of COVID-19 vaccines suggests a high likelihood of success for other vaccine targets and we see this as a growth driver in the medium to longer term, but we think COVID-19 to remain focus for shares in '22."

For an analyst ratings summary and ratings history on Moderna click here. For more ratings news on Moderna click here.

Shares of Moderna closed at $167.52 yesterday.


You May Also Be Interested In





Related Categories

Analyst Comments, Hot Comments, Hot New Coverage, New Coverage

Related Entities

UBS